Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
OVID Ovid Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: OVID
Price (delayed)
$0.3133
Market cap
$22.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.35
Enterprise value
$13.64M
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these
Highlights
Ovid Therapeutics's debt has shrunk by 68% YoY and by 2.2% QoQ
The EPS has soared by 51% YoY and by 5% QoQ
OVID's revenue is up by 16% year-on-year but it is down by 3.2% since the previous quarter
The gross profit has grown by 16% YoY but it has contracted by 3.2% from the previous quarter
OVID's quick ratio has shrunk by 53% YoY and by 8% QoQ
OVID's equity is down by 24% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of OVID
Market
Valuations
Earnings
Shares outstanding
71.11M
Market cap
$22.28M
Enterprise value
$13.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
40.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.89
Revenue
$548,000
Gross profit
$548,000
Operating income
-$57.02M
Net income
-$24.97M
EBIT
-$24.97M
EBITDA
-$23.24M
Free cash flow
-$49.6M
Per share
Balance sheet
Liquidity
EPS
-$0.35
EPS diluted
-$0.35
Free cash flow per share
-$0.7
Book value per share
$0.83
Revenue per share
$0.01
TBVPS
$1.15
Total assets
$81.65M
Total liabilities
$22.38M
Debt
$14.43M
Equity
$59.28M
Working capital
$36.61M
Debt to equity
0.24
Current ratio
4.93
Quick ratio
4.83
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-4,240.1%
Gross margin
100%
Net margin
-4,557.1%
Operating margin
-10,404.2%
Return on assets
-25.3%
Return on equity
-34.1%
Return on invested capital
-32.1%
Return on capital employed
-34.5%
Return on sales
-4,557.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OVID stock price
How has the Ovid Therapeutics stock price performed over time
Intraday
1.2%
1 week
4.12%
1 month
2.82%
1 year
-89.83%
YTD
-66.45%
QTD
0.45%
Financial performance
How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$548,000
Gross profit
$548,000
Operating income
-$57.02M
Net income
-$24.97M
Gross margin
100%
Net margin
-4,557.1%
Ovid Therapeutics's net margin has surged by 57% YoY and by 2.4% QoQ
The net income has soared by 51% YoY and by 6% from the previous quarter
The operating margin has grown by 20% YoY and by 4.8% from the previous quarter
OVID's revenue is up by 16% year-on-year but it is down by 3.2% since the previous quarter
Price vs fundamentals
How does OVID's price correlate with its fundamentals
Growth
What is Ovid Therapeutics's growth rate over time
Valuation
What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
40.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.89
The EPS has soared by 51% YoY and by 5% QoQ
OVID's price to book (P/B) is 83% less than its 5-year quarterly average of 2.3 and 53% less than its last 4 quarters average of 0.8
OVID's equity is down by 24% YoY and by 13% from the previous quarter
OVID's price to sales (P/S) is 86% less than its 5-year quarterly average of 288.1 and 58% less than its last 4 quarters average of 96.5
OVID's revenue is up by 16% year-on-year but it is down by 3.2% since the previous quarter
Efficiency
How efficient is Ovid Therapeutics business performance
The ROS has soared by 57% YoY and by 2.4% QoQ
Ovid Therapeutics's ROE has increased by 36% YoY
The return on assets has increased by 33% year-on-year but it has declined by 6% since the previous quarter
OVID's ROIC is up by 32% YoY but it is down by 16% QoQ
Dividends
What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OVID.
Financial health
How did Ovid Therapeutics financials performed over time
The total liabilities has plunged by 58% YoY and by 7% from the previous quarter
The company's current ratio has shrunk by 53% YoY and by 7% QoQ
Ovid Therapeutics's debt is 76% lower than its equity
Ovid Therapeutics's debt has shrunk by 68% YoY and by 2.2% QoQ
Ovid Therapeutics's debt to equity has plunged by 59% YoY but it has increased by 9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.